Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men

@article{Arver1997LongtermEA,
  title={Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men},
  author={S. Arver and A. Dobs and A. Meikle and K. Caramelli and L. Rajaram and S. Sanders and N. Mazer},
  journal={Clinical Endocrinology},
  year={1997},
  volume={47}
}
  • S. Arver, A. Dobs, +4 authors N. Mazer
  • Published 1997
  • Medicine
  • Clinical Endocrinology
  • An important aim in treating male hypogonadism is restoration of physiological concentrations of testosterone and its metabolites. We have assessed hormone levels, pharmacokinetics and clinical response, including safety, of a permeation‐enhanced testosterone transdermal system (TTD) in the treatment of hypogonadal men for a 12‐month period. 
    133 Citations
    Long‐term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years
    • 122
    • PDF
    Alterations in hepatic lipase and lipoprotein subfractions with transdermal testosterone replacement therapy
    • 34
    New Modalities of Transdermal Testosterone Replacement
    • 12

    References

    SHOWING 1-10 OF 31 REFERENCES
    Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    • 119
    • PDF
    Safety aspects of androgen therapy
    • 11
    Adverse dermatologic reactions to transdermal drug delivery systems.
    • 76
    Biological actions of androgens.
    • 971